Format

Send to

Choose Destination
Expert Rev Anti Infect Ther. 2011 Apr;9(4):405-13. doi: 10.1586/eri.10.178.

Immunological risk factors for infection after immunosuppressive and biologic therapies.

Author information

1
Transplant Immunology Group, Clinical Immunology Department, University Hospital Gregorio MaraƱon, Doctor Esquerdo 46, 28007 Madrid, Spain. jcarbone.hgugm@salud.madrid.org

Abstract

Immunosuppressive and biologic therapies are costly and can involve a considerable risk of infection. Noninvasive diagnostic tools for early prediction of infection before and after administration of these therapies are of major interest. Serial longitudinal immune monitoring would provide data on immunocompetence and complement clinical follow-up protocols. Biomarkers of immune response may be useful to identify patients at risk of developing infection and who could be candidates for immunosuppressant dose reduction. This article focuses on the potential use of biomarkers of immune response to predict development of infection after immunosuppressive and biologic therapies in selected settings of autoimmune disease (rituximab for treatment of rheumatoid arthritis) and solid organ transplantation.

PMID:
21504398
DOI:
10.1586/eri.10.178
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center